State of the art in diagnostics of ischemic heart disease and current recommended therapeutic approach

Česká verzia

Authors: Kateřina Bouzková
Authors place of work: Klinika kardiologie, Kardiocentrum, Institut klinické a experimentální medicíny (IKEM), Praha
Published in the journal: Čes.-slov. Patol., 56, 2020, No. 1, p. 13-17
Category: Reviews Article

Summary

Several changes have occurred during last few years in diagnostics and treatment of the ischemic heart disease, especially due to introduction of so called high-sensitive troponins, implementation of new antiplatelet drugs, using of drug-eluting stents in percutaneous coronary interventions or novel definitions of acute myocardial infarction types. The European Society of Cardiology and Czech Society of Cardiology established new recommendations for management of both acute and chronic forms of the ischemic heart disease. Recently discovered inhibitors of the PCSK9 molecule that have been slowly introduced in the clinical practice represent a breakthrough in the treatment of dyslipidemia. Future research will certainly aim at detection of early forms of the atherosclerotic involvement of the coronary arteries.

Keywords:

ischemic heart disease – revised guidelines of European Society of Cardiology/Czech Society of Cardiology – new antiplatelet drugs – inhibition of PCSK9

Zdroje

1. Staněk V. Kardiologie v praxi (1. edice). Praha: Axonite; 2014: 112-160.

2. Widimský P, Rokyta R, Hlinomaz O. Summary of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Prepared by the Czech Society of Cardiology. Cor Vasa 2016; 58(1): e4-e28.

3. Kettner J., Kautzner J. Akutní kardiologie (2. edice). Praha: Mladá fronta; 2017.

4. Kala P, Mates M, Želízko M, Rokyta R, Ošťádal P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa 2017; 59(6): e613-e644.

5. Táborský M, Kaoutzner J, Moťovská Z et al. Novinky v kardiologii 2016 (2. edice). Praha: Mladá fronta; 2016: 20-27.

6. Vojáček J, Janský P, Janota T. Third universal definition of myocardial infarction. Cor Vasa 2013; 55(3): e228-e235.

7. Želízko M, Toušek F, Skalická H. Summary of the 2013 ESC guidelines on the management of stable coronary artery disease: Prepared by the Czech Society of Cardiology. Cor Vasa 2014; 56(3): e259-e273.

8. Srbová E. ESC 2018 „Diamantová cesta“ – moderní přístup v léčbě anginy pectoris. Kardiol Rev Int Med 2018, 20(3): 238-241.

9. Vrablík M. Evolocumab – protilátka proti PCSK9 s mohutným hypolipidemických účinkem. Kardiol Rev Int Med 2015, 17(4): 362-366.

10. Čillíková K. Podmínky úhrady inhibitorů PCSK9 v ČR – aktuální stav. Kardiol Rev Int Med 2018, 20(3): 224-225.

11. Piťha J. Detekce časných stadií aterosklerózy. Interní Med 2016; 18(1): 9–13.